NeurAxis is a medical technology company focused on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults. NeurAxis is dedicated to advancing its IB-Stim therapy based on its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology through evidence-based research to drive adoption by the clinical and scientific communities. With FDA clearance for functional abdominal pain associated with IBS in children and ongoing clinical trials for multiple other conditions, NeurAxis is focused on serving the unmet healthcare needs of children and adults. Founded in 2012, NeurAxis is committed to increasing awareness and broad access to its technology for children and adults.
The IB-Stim product provides greater efficacy and safety versus standard pharmacotherapy. NeurAxis received a technology-specific CPT CAT III code[CT1] on July 1, 2022, and anticipates submitting for a CPT CAT 1 code in mid-2023. NeurAxis is adding to its existing base of written policy coverage with insurance providers.
Ticker is NRXS and it is traded on the NYSE American exchange
We do not currently have a direct stock purchase plan.
Quarterly and annual reports, as well as other SEC filings, can be accessed on the portion of our Investor Relations website or directly from the SEC at www.sec.gov.
Our fiscal year end is December 31.
We do not intend to pay cash dividends on our common stock, as we intend to retain all available funds and any future earnings to support operations and finance the growth and development of our business.
Our independent registered public accountants are RBSK Partners PC. Their address is 224 North Broadway Greensburg, IN. 47240. (812) 663-7567.
VStock Transfer. 18 Lafayette Place, Woodmere, New York 11598 (212) 82-8436.
You can view our management team by visiting the section of our website.
We will issue a national press release that includes the date of our quarterly earnings call. When the release is issued, it will be posted on the section of our website along with the details for a conference call and/or webcast to discuss the results.
You can contact NeurAxis’s Investor Relations via email at: IR@neuraxis.com.
If your shares are held in street name (by your broker), you must notify the securities firm holding your stock. If you hold stock certificates in your name, you may reach our transfer agent at the address or phone numbers below or by visiting: www.VStocktransfer.com.
VStock Transfer, LLC
18 Lafayette Place
Woodmere, New York 11598
Phone: (212) 828-8436 Ext 131
Facsimile: (646) 536-3179
www.VStockTransfer.com
If you hold stock certificates in your name, please contact our transfer agent regarding the replacement of lost certificates at the address or phone numbers below or by visiting www.VStocktransfer.com
VStock Transfer, LLC
18 Lafayette Place
Woodmere, New York 11598
Phone: (212) 828-8436 Ext 131
Facsimile: (646) 536-3179
www.VStockTransfer.com